RVRC 最新10-Q变化
将 RVRC 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-Q · 2026-08-13 与上一份 10-Q · 2026-05-14
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 管理层讨论与分析 | 文字有新增/删除 | +6 | −6 | ~10 | 31 |
| 市场风险(第3项) | 无段落级文字变化 | 0 | 0 | 0 | 1 |
| 控制与程序 | 文字有新增/删除 | 0 | 0 | ~2 | 0 |
| 法律诉讼 | 无段落级文字变化 | 0 | 0 | 0 | 1 |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
未列出(无法可靠提取或缺失):风险因素、其他信息
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-Q · 2026-08-13
In March 2026, the Company submitted an application to the Israel Innovation Authority for non-dilutive funding support related to the Nano-Mupirocin program. On May 28, 2026, the Company was notified that the application was not approved in the current review cycle. In its written decision, the Res…
The Company’s research and development expenses totaled $443 thousand for the three months period ended June 30, 2026, representing an increase of $52 thousand, or 13.3%, compared to the Company’s research and development expenses of $391 thousand for the same period in 2025. For the six months peri…
The Company’s general and administrative expenses totaled $289 thousand for the three months period ended June 30, 2026, representing a decrease of $258 thousand, or 47.2%, compared to the Company’s general and administrative expenses of $547 thousand for the same period in 2025. For the six months …
As a result of the foregoing, the Company’s operating loss totaled $732 thousand for the three months period ended June 30, 2026, representing a decrease of $206 thousand, or 22.0%, compared to the Company’s operating loss of $938 thousand for the same period in 2025. For the six months period ended…
We recognized financing expenses, net of $16 thousand for the three months period ended June 30, 2026, compared to financing expenses, net, of $101 thousand for the same period in 2025, and financing expenses, net of $2 thousand for the six months period ended June 30, 2026, compared to financing in…
相对上期删除的文字 · 来源:10-Q · 2026-05-14
In March 2026, , we submitted an application to the Israel Innovation Authority for non-dilutive funding support related to the Nano-Mupirocin program. The application is under review, and there can be no assurance that the grant will be approved or that any funding will be received. No amounts have…
The Company’s research and development expenses totaled $473,000 for the three months period ended March 31, 2026, representing an increase of $255,000, or 116.9%, compared to the Company’s research and development expenses of $218,000 for the same period in 2025. The research and development expens…
The Company’s general and administrative expenses totaled $266,000 for the three months period ended March 31, 2026, representing a decrease of $253,000, or 48.7%, compared to the Company’s general and administrative expenses of $519,000 for the same period in 2025. The decrease was primarily attrib…
As a result of the foregoing, The Company’s operating loss totaled $739,000 for the three months period ended March 31, 2026, representing an increase of $2,000, or 0.2%, compared to the Company’s operating loss of $737,000 for the same period in 2025.
We recognized financing income, net of $14,000 for the three months period ended March 31, 2026, compared to $103,000 for the same period in 2025. The decrease in financing income, net, was due to lower interest income from bank deposits during the three months period ended March 31, 2026 compared t…
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议